Open AccessPatient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
Author(s) -
Eric L. Simpson,
Andreas Wollenberg,
Robert Bissonnette,
Jonathan I. Silverberg,
Jocelyne Papacharalambous,
Linda Zhu,
Weidong Zhang,
Jean S. Beebe,
Michael S. Vincent,
Elena Peeva,
Andrew G. Bushmakin,
Joseph C. Cappelleri,
Linda Chen,
Vanja Sikirica,
Jason Xenakis
Publication year - 2021
Publication title -
dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 56
eISSN - 2162-5220
pISSN - 1710-3568
DOI - 10.1097/der.0000000000000725
Subject(s) - medicine , atopic dermatitis , eczema area and severity index , dermatology life quality index , quality of life (healthcare) , placebo , hospital anxiety and depression scale , depression (economics) , rating scale , severity of illness , dermatology , anxiety , physical therapy , disease , psychiatry , alternative medicine , psychology , developmental psychology , nursing , pathology , economics , macroeconomics
Moderate-to-severe atopic dermatitis (AD) is inadequately controlled with current treatments for many patients. Abrocitinib is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of AD.